In this ARC TALKS webinar, ARC's own Kristen Hsu presented the most current updates for the clinical trial landscape, with a focus on ATTR amyloidosis. Kristen will also explored the direction future research.
The webinar concluded with a Q and A session.
This webinar was original presented on June 20, 2024.
0:00 - Intro
4:19 - What is a Clinical Trial?
8:06 - Should I Participate in a Trial?
10:13 - ATTR Amyloidosis Clinical Trials
14:00 - Clinical Trials Currently Recruiting
15:29 - MAGNITUDE (NTLA-2001; CRISPR Gene Editing)
21:36 - DepleTTR-CM (ALXN2220; Amyloid Depleter)
24:35 - Ongoing Clinical Trials
24:57 - ATTRibute-CM (Acoramidis; TTR Stabilizer)
26:16 - HELIOS-B (Vutrisiran; Gene Silencer)
27:25 - CARDIO-TTRansform (Eplontersen; Gene Silencer)
28:38 - Coramitug (NNC6019-0001; Anti-Amyloid Fibril)
29:39 - AT-02 (Pan-Amyloid Anti-Fibril)
31:17 - Planned Future Trials
33:14 - Other Clinical Trials
37:25 - How to Find Clinical Trials
42:00 - Q&A Session
42:33 - What is the upcoming study for hereditary ATTR carriers?
43:12 - What is a “knockdown” TTR drug?
45:09 - Does race have an impact on treatment?
46:24 - Are there studies looking at early diagnosis/natural progression of ATTR?
48:35 - How can people outside of the US participate in studies and trials?
49:44 - Are there clinical trials looking to prevent heart involvement?